Immatics presented Phase 1 clinical trial data for its IMA401 TCR bispecific targeting MAGEA4/8, showing durable responses and good tolerability in heavily pretreated solid tumor patients, including melanoma and head and neck cancer. The data, also published in Nature Medicine, support combining IMA401 with IMA402 (targeting PRAME) to enhance treatment for squamous cell non-small cell lung cancer (sqNSCLC), where over 90% of patients express one or both targets. Enrollment for the combination trial is underway with initial results expected in 2027, marking a significant step in developing off-the-shelf immunotherapies for solid tumors.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
